Targeting ubiquitination for cancer therapies

被引:87
|
作者
Morrow, John Kenneth [1 ,2 ]
Lin, Hui-Kuan [3 ]
Sun, Shao-Cong [4 ]
Zhang, Shuxing [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Expt Therapeut, Integrated Mol Discovery Lab, Houston, TX 77030 USA
[2] Univ Texas Grad Sch Biomed Sci, Houston, TX 77030 USA
[3] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[4] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
关键词
cancer therapeutics; deubiquitinase; E3 ligase inhibition; high-throughput virtual screening; hot spots; in silico modeling; SCF complex; Skp2; inhibitors; small molecule inhibitors; ubiquitination; SMALL-MOLECULE INHIBITOR; ACTIVE PROTEASOME INHIBITOR; SINGLE-AGENT CARFILZOMIB; CELL-CYCLE ARREST; LIGASE CBL-B; MULTIPLE-MYELOMA; OPEN-LABEL; DEUBIQUITINASE INHIBITION; NEDD8-ACTIVATING ENZYME; UBC13-UEV1A INTERACTION;
D O I
10.4155/fmc.15.148
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ubiquitination, the structured degradation and turnover of cellular proteins, is regulated by the ubiquitin-proteasome system (UPS). Most proteins that are critical for cellular regulations and functions are targets of the process. Ubiquitination is comprised of a sequence of three enzymatic steps, and aberrations in the pathway can lead to tumor development and progression as observed in many cancer types. Recent evidence indicates that targeting the UPS is effective for certain cancer treatment, but many more potential targets might have been previously overlooked. In this review, we will discuss the current state of small molecules that target various elements of ubiquitination. Special attention will be given to novel inhibitors of E3 ubiquitin ligases, especially those in the SCF family.
引用
收藏
页码:2333 / 2350
页数:18
相关论文
共 50 条
  • [21] Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies
    Galbraith, Norman J.
    Wood, Colin
    Steele, Colin W.
    CANCERS, 2021, 13 (14)
  • [22] Targeting the immune system: a new horizon of cancer therapies
    Dong, Chen
    NATIONAL SCIENCE REVIEW, 2015, 2 (01) : 10 - 12
  • [23] ADRB2-Targeting Therapies for Prostate Cancer
    Kulik, George
    CANCERS, 2019, 11 (03):
  • [24] Macropinocytosis confers resistance to therapies targeting cancer anabolism
    Jayashankar, Vaishali
    Edinger, Aimee L.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [25] Targeting base excision repair to improve cancer therapies
    Sharma, Ricky A.
    Dianov, Grigory L.
    MOLECULAR ASPECTS OF MEDICINE, 2007, 28 (3-4) : 345 - 374
  • [26] Targeting the immune system: a new horizon of cancer therapies
    Chen Dong
    National Science Review, 2015, 2 (01) : 10 - 12
  • [27] Investigational therapies targeting the ErbB family in oesophagogastric cancer
    Moorcraft, Sing Yu
    Chau, Ian
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (10) : 1349 - 1363
  • [28] Epigenetic targeting and reports on cancer-related therapies
    Searle, Ben
    IDRUGS, 2006, 9 (08) : 526 - 528
  • [29] Past, Present, and Future of Targeting Ras for Cancer Therapies
    Tan, Zhi
    Zhang, Shuxing
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2016, 16 (05) : 345 - 357
  • [30] Macropinocytosis confers resistance to therapies targeting cancer anabolism
    Vaishali Jayashankar
    Aimee L. Edinger
    Nature Communications, 11